Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011 Jun. 164(6):1335-41. [QxMD MEDLINE Link].
Wieczorek IT, Propert KJ, Okawa J, Werth VP. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014 Mar. 150 (3):291-6. [QxMD MEDLINE Link].
Prystowsky SD, Gilliam JN. Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus. Arch Dermatol. 1975 Nov. 111(11):1448-52. [QxMD MEDLINE Link].
Elman SA, Joyce C, Costenbader KH, Merola JF. Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study. Clin Exp Dermatol. 2020 Jan. 45 (1):89-91. [QxMD MEDLINE Link].
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug. 64 (8):2677-86. [QxMD MEDLINE Link].
Lehmann P, Hölzle E, Kind P, Goerz G, Plewig G. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol. 1990 Feb. 22(2 Pt 1):181-7. [QxMD MEDLINE Link].
Kahn JS, Deverapalli SC, Rosmarin DM. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol. 2018 Aug. 57 (8):1007-1014. [QxMD MEDLINE Link].
Solé C, Gimenez-Barcons M, Ferrer B, Ordi-Ros J, Cortés-Hernández J. Microarray study reveals a transforming growth factor-β-dependent mechanism of fibrosis in discoid lupus erythematosus. Br J Dermatol. 2016 Aug. 175 (2):302-13. [QxMD MEDLINE Link].
Solé C, Domingo S, Ferrer B, Moliné T, Ordi-Ros J, Cortés-Hernández J. MicroRNA Expression Profiling Identifies miR-31 and miR-485-3p as Regulators in the Pathogenesis of Discoid Cutaneous Lupus. J Invest Dermatol. 2019 Jan. 139 (1):51-61. [QxMD MEDLINE Link].
Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009 Mar. 145(3):249-53. [QxMD MEDLINE Link].
Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet CJ Jr, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res (Hoboken). 2015 May. 67 (6):817-28. [QxMD MEDLINE Link].
Drenkard C, Parker S, Aspey LD, Gordon C, Helmick CG, Bao G, et al. Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. Arthritis Care Res (Hoboken). 2019 Jan. 71 (1):95-103. [QxMD MEDLINE Link].
Izmirly P, Buyon J, Belmont HM, Sahl S, Wan I, Salmon J, et al. Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Sci Med. 2019. 6 (1):e000344. [QxMD MEDLINE Link].
Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, LoMonico J, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 May. 64 (5):849-58. [QxMD MEDLINE Link].
Achtman J, Kling MA, Feng R, Okawa J, Werth VP. A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. J Am Acad Dermatol. 2016 Feb. 74 (2):377-9. [QxMD MEDLINE Link].
Gordon H, Chandran A, Vandal AC, Yung A, Jarrett P. The relationship between disease severity and quality of life in discoid lupus erythematosus. Br J Dermatol. 2017 Oct. 177 (4):1134-1135. [QxMD MEDLINE Link].
Tao J, Zhang X, Guo N, et al. Squamous cell carcinoma complicating discoid lupus erythematosus in Chinese patients: review of the literature, 1964-2010. J Am Acad Dermatol. 2012 Apr. 66(4):695-6. [QxMD MEDLINE Link].
Zaalberg A, Moradi Tuchayi S, Ameri AH, Ngo KH, Cunningham TJ, Eliane JP, et al. Chronic inflammation promotes skin carcinogenesis in cancer-prone discoid lupus erythematosus. J Invest Dermatol. 2018 Jul 17. [QxMD MEDLINE Link].
Eastham AB, Vleugels RA. Cutaneous lupus erythematosus. JAMA Dermatol. 2014 Mar. 150(3):344. [QxMD MEDLINE Link].
Merola JF, Prystowsky SD, Iversen C, Gomez-Puerta JA, Norton T, Tsao P, et al. Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. J Am Acad Dermatol. 2013 Jul. 69 (1):19-24. [QxMD MEDLINE Link].
Parish LC, Kennedy RJ, Hurley J. Palmar lesions in lupus erythematosus. Arch Dermatol. 1967 Sep. 96(3):273-6. [QxMD MEDLINE Link].
Spann CR, Callen JP, Klein JB, Kulick KB. Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesions. J Rheumatol. 1988 Feb. 15(2):256-61. [QxMD MEDLINE Link].
Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol. 1999 Jan. 26(1):68-72. [QxMD MEDLINE Link].
Elman SA, Joyce C, Nyberg F, Furukawa F, Goodfield M, Hasegawa M, et al. Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. J Am Acad Dermatol. 2017 Aug. 77 (2):261-267. [QxMD MEDLINE Link].
Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013 Jan. 12 (3):444-54. [QxMD MEDLINE Link].
Kim A, O'Brien J, Tseng LC, Zhang S, Chong BF. Autoantibodies and disease activity in patients with discoid lupus erythematosus. JAMA Dermatol. 2014 Jun. 150 (6):651-4. [QxMD MEDLINE Link].
Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010 Mar. 62(3):863-8. [QxMD MEDLINE Link].
Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011 Feb. 13(1):77-80. [QxMD MEDLINE Link].
Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005 Jul. 153(1):157-62. [QxMD MEDLINE Link].
Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991 Apr. 127(4):515-22. [QxMD MEDLINE Link].
Nahmias Z, Nambudiri VE, Vleugels RA. Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions. J Am Acad Dermatol. 2016 Jul. 75 (1):210-2. [QxMD MEDLINE Link].
Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009 Mar. 145(3):303-6. [QxMD MEDLINE Link]. [Full Text].
Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol. 2006 Feb. 47(1):13-27. [QxMD MEDLINE Link].
James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007. 16(6):401-9. [QxMD MEDLINE Link].
Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011 Oct. 131(10):1981-6. [QxMD MEDLINE Link].
Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011 Feb. 118(2):415-22. [QxMD MEDLINE Link].
Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011 Aug. 13 (4):300-7. [QxMD MEDLINE Link].
Mittal L, Zhang L, Feng R, Werth VP. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. J Am Acad Dermatol. 2018 Jan. 78 (1):100-106.e1. [QxMD MEDLINE Link].
Alves P, Bashir MM, Wysocka M, Zeidi M, Feng R, Werth VP. Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. J Investig Dermatol Symp Proc. 2017 Oct. 18 (2):S57-S63. [QxMD MEDLINE Link].
Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011 Oct. 131(10):1981-6. [QxMD MEDLINE Link].
Chasset F, Francès C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015 Apr. 72 (4):634-9. [QxMD MEDLINE Link].
Gallego H, Crutchfield CE 3rd, Lewis EJ, Gallego HJ. Report of an association between discoid lupus erythematosus and smoking. Cutis. 1999 Apr. 63(4):231-4. [QxMD MEDLINE Link].
Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol. 1998 Sep. 25(9):1716-9. [QxMD MEDLINE Link].
Lipsker D, Boeckler P, Hauptmann G. Cigarette smoking and lupus erythematosus. Dermatology. 2006. 212(3):262. [QxMD MEDLINE Link].
Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2012 Mar. 148(3):317-22. [QxMD MEDLINE Link]. [Full Text].
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun. 123 (6):1386-94. [QxMD MEDLINE Link].
Spinelli FR, Moscarelli E, Ceccarelli F, Miranda F, Perricone C, Truglia S, et al. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. Lupus. 2018 Sep. 27 (10):1616-1623. [QxMD MEDLINE Link].
Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 Oct. 65(4):717-21. [QxMD MEDLINE Link].
Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007 Jun. 156(6):1321-7. [QxMD MEDLINE Link].
Kindle SA, Wetter DA, Davis MD, Pittelkow MR, Sciallis GF. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. Int J Dermatol. 2016 Aug. 55 (8):e431-9. [QxMD MEDLINE Link].
Okon L, Rosenbach M, Krathen M, Rose M, Propert K, Okawa J, et al. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. J Am Acad Dermatol. 2014 Mar. 70 (3):583-4. [QxMD MEDLINE Link].
Rosmarin D. Open label phase 2 pilot trial of oral tofactinib in adult subjects with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE). Report No.: NCT03159936. 2017.
De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Jr. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol. 2012 Oct. 11 (10):1224-6. [QxMD MEDLINE Link].
Tenti S, Fabbroni M, Mancini V, Russo F, Galeazzi M, Fioravanti A. Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: A case report and review of the literature. Autoimmun Rev. 2018 Aug. 17 (8):791-795. [QxMD MEDLINE Link].
Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov. 71 (11):1833-8. [QxMD MEDLINE Link].
Kuhn A, Landmann A, Wenzel J. Advances in the treatment of cutaneous lupus erythematosus. Lupus. 2016 Jul. 25 (8):830-7. [QxMD MEDLINE Link].
Herold M, Richmond NA, Montuno MA, Wesson SK, Motaparthi K. Rapamycin for refractory discoid lupus erythematosus. Dermatol Ther. 2018 Sep. 31 (5):e12631. [QxMD MEDLINE Link].
Rerknimitr P, Tekacharin N, Panchaprateep R, Wititsuwannakul J, Tangtanatakul P, Hirankarn N, et al. Pulsed-dye laser as an adjuvant treatment for discoid lupus erythematosus: a randomized, controlled trial. J Dermatolog Treat. 2019 Feb. 30 (1):81-86. [QxMD MEDLINE Link].
Erceg A, Bovenschen HJ, van de Kerkhof PC, de Jong EM, Seyger MM. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol. 2009 Apr. 60(4):626-32. [QxMD MEDLINE Link].
Callen JP. Management of "refractory" skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. 2005 Oct. 19(5):767-84. [QxMD MEDLINE Link].
Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol. 1993 Sep-Oct. 11(5):487-93. [QxMD MEDLINE Link].
Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus. 2005. 14(6):434-9. [QxMD MEDLINE Link].
Duong DJ, Spigel GT, Moxley RT 3rd, Gaspari AA. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol. 1999 Sep. 135(9):1079-87. [QxMD MEDLINE Link].
Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB Jr, Sutej PG. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. 2003 Jan. 139(1):50-4. [QxMD MEDLINE Link].
Newton RC, Jorizzo JL, Solomon AR Jr, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol. 1986 Feb. 122(2):170-6. [QxMD MEDLINE Link].
Tsianakas A, Herzog S, Landmann A, Patsinakidis N, Perusquía Ortiz AM, Bonsmann G, et al. Successful treatment of discoid lupus erythematosus with fumaric acid esters. J Am Acad Dermatol. 2014 Jul. 71(1):e15-7. [QxMD MEDLINE Link].
Debu A, Girard C, Bessis D. Discoid lupus erythematosus successfully treated by photodynamic therapy. Br J Dermatol. 2014 Sep 12. [QxMD MEDLINE Link].
Turan E, Sinem Bagci I, Turgut Erdemir A, Salih Gurel M. Successful treatment of generalized discoid lupus erythematosus with imiquimod cream 5%: a case report and review of the literature. Acta Dermatovenerol Croat. 2014. 22(2):150-9. [QxMD MEDLINE Link].